MGMT methylation has become the main prognostic factor in GBM patient management (8, 34), but some cases have been reported in which MGMT-methylated cells are resistant to TMZ and MGMT-expressing cells are sensitive to the drug. The gene discussed is MGMT; the disease is glioblastoma.